FIRST-IN-HUMAN PHASE 1/2 TRIAL TO EVALUATE THE SAFETY AND INITIAL CLINICAL ACTIVITY OF DUOBODY®-CD40x4-1BB (GEN1042) IN PATIENTS WITH ADVANCED SOLID TUMORS

被引：3

作者：

Johnson, Melissa ^{[1
]}

Lopez, Juanita ^{[2
]}

LoRusso, Patricia ^{[3
]}

Bauman, Jessica ^{[4
]}

Haggstrom, Daniel ^{[5
]}

Lagkadinou, Eleni ^{[6
]}

Bajaj, Gaurav ^{[7
]}

Tureci, Ozlem

Adams, Homer, III

Sahin, Ugur ^{[6
]}

Fu, Yali ^{[7
]}

Ahmadi, Tahamtan ^{[7
]}

Rohrberg, Kristoffer ^{[8
]}

机构：

[1] Sarah Cannon Res Inst, Nashville, TN USA

[2] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England

[3] Yale Canc Ctr, New Haven, CT USA

[4] Fox Chase Canc Ctr, Philadelphia, PA USA

[5] Levine Canc Inst, Charlotte, NC USA

[6] BioNTech SE, Mainz, Germany

[7] Genmab, Princeton, NJ USA

[8] Univ Copenhagen Hosp, Rigshosp, Copenhagen, Denmark

来源：

关键词：

D O I：

10.1136/jitc-2021-SITC2021.493

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

493

引用

页码：A525 / A525

页数：1